Clarity AD CSF Substudy Findings on Lecanemab Treatment and α-Synuclein Co-Pathology Presented at CTAD 2026Lecanemab showed favorable results on clinical assessment scores at 18 months, including among individuals with early Alzheimer’s disease (AD) who were α-synuclein positive, a subgroup associated with higher amyloid burden and faster clinical decline

  • R&D
  • Products

Our news releases are intended to disclose corporate information and are not intended for the promotion or advertising of prescription pharmaceuticals or investigational products, nor are they intended to provide medical advice.
Please note that the information contained in news releases is current as of the date of publication.